drugset

Drugs / BWC0977

Follow last change Aug 2026 re-read 3 minutes ago

BWC0977

Investigated by: Bugworks Research Inc. · Avance Clinical Pty Ltd. · Nucleus Network Ltd

Trials 3

today NCT07029932 · Ph 1 NCT05942820 · Ph 1 NCT05088421 · Ph 1

20222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT07029932	Oct 2025 → Jun 2026 overdue	infectious disease	Bugworks Research Inc.	Recruiting	No outcome recorded
Phase 1	NCT05942820	Aug 2023 → Jan 2024	bacterial infectious disease	Bugworks Research Inc.	Terminated	No outcome recorded
Phase 1	NCT05088421	Nov 2021 → Dec 2022	bacterial infectious disease	Bugworks Research Inc.	Completed	Met primary

Press releases naming this drug 2 releases

Date	Issuer	Release
2025-07-21	Bugworks Research Inc.	GARDP and Bugworks expand strategic partnership to accelerate development of an oral formulation of BWC0977 to treat serious bacterial infections bugworksresearch.com ↗
2024-06-11	Bugworks Research Inc.	– The Global Antibiotic Research & Development Partnership (GARDP) and Bugworks Research Inc. (Bugworks) today announced a collaboration agreement to co-develop an innovative compound (BWC0977) with broad-spectrum antibiotic activity against multidrug-resistant bacteria that cause life-threatening infections. Under the agreement, GARDP will provide up to US$20 million to Bugworks in technical and financial support for the pharmaceutical and clinical co-development of BWC0977. In return, Bugworks has granted GARDP manufacturing and commercialization rights for BWC0977 in 146 countries, almost all of which are low- or middle-income (LMICs). BWC0977 has in vitro activity against a broad spectrum of pathogens that lead to serious hospital-acquired infections like pneumonia, bloodstream infections and complicated urinary tract infections. Among these pathogens are WHO critical priority pathogens, carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae, for which few treatment options exist. According to the GRAM study, these two pathogens alone account for over one-fifth of deaths associated with antimicrobial resistance (AMR) in 2019. The study also shows that, in many countries around the world, over 80% of A. baumannii clinical isolates were carbapenem- resistant. “We are excited to work with Bugworks to make key investments at this critical stage in the development of compound BWC0977,” said Manica Balasegaram, Executive Director of GARDP. “Many compounds in the antibiotic pipeline lack innovative characteristics and fail to target priority pathogens. In contrast, BWC0977 stands out for its novelty and potential to address unmet public health needs.” “Bugworks is delighted to partner with GARDP to advance compound BWC0977 through clinical development to treat a variety of drug-resistant bacterial infections,” said Anand Anandkumar, co-founder and CEO of Bugworks. “An overarching goal of this partnership is to enable access to this compound simultaneously in Western countries and in LMICs with high AMR burden. We are grateful to CARB-X for their continued support for BWC0977 from lead optimization to human clinical trials, thus enabling the asset to enter the GARDP collaborative orbit.” The development of BWC0977 reflects the bolstering of the global health ecosystem to respond to the AMR crisis. Bugworks was set up in 2014 and incubated at the Centre for Cellular and Molecular Platforms (C-CAMP) in Bengaluru, India. Since 2017, CARB-X has provided critical support for the pre-clinical development and first-in- human (phase 1) clinical study of this compound, including US$12.47 million in funding. GARDP will now collaborate with Bugworks to further develop BWC0977 and, upon approval, enable global access. “We are proud of our financial and non-financial support for the Bugworks programme, which began in lead optimization, delivered BWC0977 as a development candidate and ultimately commenced a first-in-human programme,” said Erin Duffy, R&D Chief at CARB-X. “Now that this compound has been primed for advanced development, we look forward to GARDP’s support in bringing this potential novel, broad-spectrum antibiotic to patients.” GARDP’s technical and financial support of this project is tied to the successful completion of key R&D milestones that align with GARDP’s public health objectives. GARDP will initially bring expertise and financial support for critical aspects of BWC0977’s pharmaceutical development, including product formulation. Later investments will support clinical development and chemistry, manufacturing and controls activities to ensure that the final product is suitable for use in diverse countries and contexts, including low-resource settings. bugworksresearch.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	BWC0977	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07029932 ↗ 2 NCT05942820 ↗ NCT05088421 ↗
Action	Inhibit	“selectively inhibits bacterial DNA replication via inhibition of DNA gyrase and topoisomerase IV.” PMID 39294149 ↗ Sep 2024
Route	Intravenous	“single and multiple intravenous doses of BWC0977 when administered to healthy adult volunteers.” NCT05088421 ↗